IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
zer land) Epogin (epoetin beta) which has been filed for ad di tional do mes tic ap proval in chemotherapy
induced anemia.
TAK 442, an orally ac tive, se lec tive and com pet i tive in hib i tor of ac ti vated fac tor Xa, as a po ten tial ther -
apy for ve nous or ar te rial thromboembolism, such as pul mo nary em bo lism and ce re bral in farc tion.
Takeda ini ti ated a US/Eu ro pean phase II trial of TAK 442 in 2008 and phase I eval u a tion was also re -
ported to be underway in Japan in 2009.
Cardiovascular System Agents
azilsartan + pioglitazone — C9C III
azilsartan medoxomil TAK 491 C9C III
azilsartan TAK 536 C9C II
epa/dha agent TAK 085 C10A9 II
ARB for hypertension TAK 591 C9C I
AZILSARTAN + PIOGLITAZONE, a fixed com bi na tion of pioglitazone, a thiazolidinedione, plus
azilsartan, an an gio ten sin II re cep tor an tag o nist, for the po ten tial treat ment of Type 2 di a be tes as so ci -
ated with hy per ten sion. A US phase III trial pro gram of the prod uct in pa tients with Type 2 di a be tes as so -
ci ated with hy per ten sion began in the USA in 2006.
TAK 491, an an gio ten sin II re cep tor an tag o nist with po ten tial in the treat ment of hy per ten sion was un -
der go ing phase III eval u a tion in Eu rope and the USA in 2009. A ran dom ized, dou ble-blind, pla cebo-con -
trolled phase II trial, be ing con ducted in the USA, Mex ico and Peru, eval u ated the safety, ef fi cacy and
tolerability of treat ment with TAK 491 for eight weeks in ap prox i mately 420 pa tients with hy per ten sion.
The pri mary endpoint was diastolic blood pressure.
TAK 491 is ex pected to have a stron ger antihypertensive ac tion and to dis play a su pe rior pro file in im -
prov ing in su lin re sis tance and de creas ing proteinuria com pared with mar keted an gio ten sin receptor
blockers.
TAK 536 (azilisartan) is an an gio ten sin II re cep tor an tag o nist, in phase II de vel op ment for the treat ment
of hy per ten sion in the USA and Eu rope and also en tered phase II tri als in Ja pan in 2007, all re ported to be
ongoing in 2009.
In July 2006, Takeda be gan a phase III trial pro gram of a fixed com bi na tion of pioglitazone plus TAK 536
for the treat ment of Type 2 di a be tes as so ci ated with hy per ten sion (see sep a rate drug record).
OMACOR (TAK 085), omega-3-acid ethyl es ters, en tered phase II tri als for the treat ment of
hyperlipidemia in Ja pan with Takeda in 2007, on go ing in 2009. In 2005, Takeda li censed the Jap a nese
rights to Omacor (TAK 085) from Pronova.
TAK 591, an an gio ten sin II re cep tor blocker was in phase I tri als for the treat ment of hy per ten sion in
2009.
© 2009 IMS Health In cor po rated or its af fil i ates Page 70